Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease | Zendy

Larisa Broglie | Zendy; Alfred Rademaker | Zendy; John P. Galvin | Zendy; Ayita Ray | Zendy; William T. Tse | Zendy; Reggie Duerst | Zendy; Jennifer Schneiderman | Zendy; Morris Kletzel | Zendy; Sonali Chaudhury | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease

Author(s) -

Larisa Broglie,

Alfred Rademaker,

John P. Galvin,

Ayita Ray,

William T. Tse,

Reggie Duerst,

Jennifer Schneiderman,

Morris Kletzel,

Sonali Chaudhury

Publication year - 2018

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2017.12.003

Subject(s) - calprotectin , feces , albumin , host (biology) , medicine , serum albumin , gastroenterology , disease , biology , microbiology and biotechnology , inflammatory bowel disease , genetics

Acute graft versus host disease (aGVHD) affects approximately 30-60% of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research